Dysregulation of Nociceptin/Orphanin FQ and Dynorphin Systems in the Extended Amygdala of Alcohol Preferring Marchigian Sardinian (msP) Rats.

Szczegóły
Abstrakt

Tytuł:: Dysregulation of Nociceptin/Orphanin FQ and Dynorphin Systems in the Extended Amygdala of Alcohol Preferring Marchigian Sardinian (msP) Rats.
Autorzy:: Caputi FF; Department. of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Irnerio 48, 40126 Bologna, Italy.
Stopponi S; Pharmacology Unit, School of Pharmacy, University of Camerino, Madonna delle Carceri, 62032 Camerino, Italy.
Rullo L; Department. of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Irnerio 48, 40126 Bologna, Italy.
Palmisano M; Department. of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Irnerio 48, 40126 Bologna, Italy.
Ubaldi M; Pharmacology Unit, School of Pharmacy, University of Camerino, Madonna delle Carceri, 62032 Camerino, Italy.
Candeletti S; Department. of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Irnerio 48, 40126 Bologna, Italy.
Ciccocioppo R; Pharmacology Unit, School of Pharmacy, University of Camerino, Madonna delle Carceri, 62032 Camerino, Italy.
Romualdi P; Department. of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Irnerio 48, 40126 Bologna, Italy.
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2021 Feb 28; Vol. 22 (5). Date of Electronic Publication: 2021 Feb 28.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:: Alcohol Drinking/*physiopathology
Alcoholism/*pathology
Amygdala/*pathology
Dynorphins/*pharmacology
Ethanol/*toxicity
Opioid Peptides/*pharmacology
Peptide Fragments/*pharmacology
Receptors, Opioid/*metabolism
Alcoholism/etiology ; Amygdala/drug effects ; Amygdala/metabolism ; Animals ; Behavior, Animal ; Male ; Neurotransmitter Agents/pharmacology ; Rats ; Rats, Wistar ; Receptors, Opioid/genetics
References:: Addict Biol. 2011 Apr;16(2):238-50. (PMID: 21182574)
J Neurosci. 2004 May 26;24(21):5022-30. (PMID: 15163695)
Brain Res. 2010 Feb 16;1314:145-61. (PMID: 20026088)
Front Neurosci. 2013 Aug 30;7:156. (PMID: 24009552)
J Neurosci. 1992 Jul;12(7):2439-50. (PMID: 1319476)
Psychopharmacology (Berl). 2014 Dec;231(23):4561-8. (PMID: 24858375)
Biol Psychiatry. 2007 Jan 1;61(1):4-12. (PMID: 16533497)
Recent Dev Alcohol. 2003;16:263-81. (PMID: 12638642)
Trends Neurosci. 2014 Apr;37(4):219-27. (PMID: 24636458)
Curr Top Behav Neurosci. 2013;13:3-30. (PMID: 21744309)
Br J Pharmacol. 2002 May;136(2):303-11. (PMID: 12010780)
Ann N Y Acad Sci. 2001 Jun;937:1-26. (PMID: 11458532)
J Mol Neurosci. 1997 Jun;8(3):165-79. (PMID: 9297630)
J Neurosci. 2015 May 27;35(21):8232-44. (PMID: 26019338)
J Neurochem. 2003 Jun;85(5):1139-47. (PMID: 12753073)
Addict Biol. 2013 May;18(3):425-33. (PMID: 21507157)
Front Behav Neurosci. 2017 Nov 28;11:233. (PMID: 29234279)
Int J Mol Sci. 2019 Aug 17;20(16):. (PMID: 31426473)
Biol Psychiatry. 2015 May 15;77(10):859-69. (PMID: 25433901)
Alcohol Clin Exp Res. 2011 Apr;35(4):747-55. (PMID: 21223310)
Neuroscience. 1996 Nov;75(2):333-7. (PMID: 8930999)
Psychopharmacology (Berl). 2004 Mar;172(2):170-8. (PMID: 14624331)
Front Behav Neurosci. 2017 May 11;11:81. (PMID: 28553209)
Alcohol. 2014 May;48(3):243-52. (PMID: 24721195)
Expert Rev Mol Diagn. 2001 May;1(1):92-101. (PMID: 11901805)
Addict Biol. 2013 May;18(3):467-79. (PMID: 22804785)
Neuroscience. 2015 Dec 3;310:665-73. (PMID: 26459016)
Int Rev Neurobiol. 2017;136:275-291. (PMID: 29056154)
Neuropsychopharmacology. 2009 Apr;34(5):1198-208. (PMID: 18563062)
Alcohol Clin Exp Res. 2008 Jun;32(6):909-20. (PMID: 18445109)
Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15236-41. (PMID: 17015825)
Physiol Behav. 2004 Aug;82(1):63-8. (PMID: 15234592)
Alcohol Res. 2016;38(1):7-15. (PMID: 27159807)
Brain Res. 2015 Dec 2;1628(Pt A):60-7. (PMID: 25801118)
Psychopharmacology (Berl). 2008 Mar;196(4):523-31. (PMID: 17989958)
Neuropsychopharmacology. 2015 Oct;40(11):2555-65. (PMID: 25872917)
J Neurosci Methods. 1980 Dec;3(2):129-49. (PMID: 6110810)
Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14854-8. (PMID: 9405703)
Eur J Pharmacol. 2000 Sep 15;404(1-2):153-9. (PMID: 10980274)
Neuroreport. 1999 Feb 25;10(3):541-6. (PMID: 10208586)
Nat Rev Neurosci. 2013 Sep;14(9):609-25. (PMID: 23942470)
Br J Pharmacol. 2020 Apr;177(7):1525-1537. (PMID: 31713848)
Adv Exp Med Biol. 1991;295:1-42. (PMID: 1776564)
Neuropsychopharmacology. 2016 Jan;41(1):103-25. (PMID: 26096838)
Brain Res. 2015 Dec 2;1628(Pt A):68-81. (PMID: 25451116)
Biol Psychiatry. 2016 Mar 15;79(6):427-9. (PMID: 26893193)
J Neurosci. 2009 Oct 28;29(43):13494-502. (PMID: 19864562)
J Mol Neurosci. 2013 Feb;49(2):312-9. (PMID: 22684622)
Psychopharmacology (Berl). 2015 Mar;232(6):1083-93. (PMID: 25260340)
Alcohol Clin Exp Res. 2019 Oct;43(10):2167-2178. (PMID: 31386211)
J Neurosci. 2014 Jan 8;34(2):363-72. (PMID: 24403138)
FASEB J. 2008 Jul;22(7):2393-404. (PMID: 18310464)
Addict Biol. 2007 Mar;12(1):30-4. (PMID: 17407495)
J Neurosci. 2004 Nov 17;24(46):10542-52. (PMID: 15548669)
Eur J Pharmacol. 2015 Apr 15;753:73-87. (PMID: 25583178)
Neuropsychopharmacology. 2001 Feb;24(2):97-129. (PMID: 11120394)
Drug Alcohol Depend. 2015 Oct 1;155:68-75. (PMID: 26361715)
Psychopharmacology (Berl). 1999 Jan;141(2):220-4. (PMID: 9952048)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Neuropharmacology. 2009;56 Suppl 1:18-31. (PMID: 18725236)
Int J Neuropsychopharmacol. 2014 Feb;17(2):313-22. (PMID: 24103311)
Psychopharmacology (Berl). 1999 May;144(2):151-7. (PMID: 10394996)
Neuropeptides. 2014 Aug;48(4):189-97. (PMID: 24894718)
Nat Neurosci. 2007 Aug;10(8):935-6. (PMID: 17657232)
Peptides. 2006 Sep;27(9):2193-200. (PMID: 16730097)
Lancet Psychiatry. 2016 Aug;3(8):760-773. (PMID: 27475769)
Psychopharmacology (Berl). 2016 Oct;233(19-20):3553-63. (PMID: 27515665)
Addict Biol. 2006 Sep;11(3-4):339-55. (PMID: 16961763)
Alcohol Clin Exp Res. 2004 Nov;28(11):1609-12. (PMID: 15547445)
JAMA. 2018 Aug 28;320(8):815-824. (PMID: 30167705)
Drug Alcohol Depend. 2019 Apr 1;197:127-133. (PMID: 30818133)
Biol Psychiatry. 2008 Aug 1;64(3):211-8. (PMID: 18367152)
Pharmacol Ther. 2014 Mar;141(3):283-99. (PMID: 24189487)
Alcohol Clin Exp Res. 2017 Apr;41(4):836-845. (PMID: 28281290)
J Pharmacol Exp Ther. 2003 Jan;304(1):310-8. (PMID: 12490606)
Alcohol. 2020 Aug;86:121-128. (PMID: 31978460)
Psychopharmacology (Berl). 2020 Jun;237(6):1633-1642. (PMID: 32095915)
Anal Biochem. 1987 Apr;162(1):156-9. (PMID: 2440339)
Grant Information:: AA014351 United States DA NIDA NIH HHS; 2017SXEXT5 The Italian Ministry of University and Research PRIN 2017; RFO2017 University of Bologna
Contributed Indexing:: Keywords: BDNF; CRF; CRF-R1; KOP; NOP; Trk-B; addiction; dynorphin; ethanol; nociceptin
Substance Nomenclature:: 0 (Neurotransmitter Agents)
0 (Opioid Peptides)
0 (Peptide Fragments)
0 (Receptors, Opioid)
0 (nociceptin orphanin FQ(1-17)OH)
3K9958V90M (Ethanol)
74913-18-1 (Dynorphins)
Entry Date(s):: Date Created: 20210306 Date Completed: 20210512 Latest Revision: 20210512
Update Code:: 20240104
PubMed Central ID:: PMC7957504
DOI:: 10.3390/ijms22052448
PMID:: 33671048
: Czasopismo naukowe

Pełny tekst

Previous studies have shown that genetically selected Marchigian Sardinian alcohol-preferring (msP) rats consume excessive amounts of ethanol to self-medicate from negative moods and to relieve innate hypersensitivity to stress. This phenotype resembling a subset of alcohol use disorder (AUD) patients, appears to be linked to a dysregulation of the equilibrium between stress and antistress mechanisms in the extended amygdala. Here, comparing water and alcohol exposed msP and Wistar rats we evaluate the transcript expression of the anti-stress opioid-like peptide nociceptin/orphanin FQ (N/OFQ) and its receptor NOP as well as of dynorphin (DYN) and its cognate κ-opioid receptor (KOP). In addition, we measured the transcript levels of corticotropin-releasing factor (CRF), CRF receptor 1 (CRF1R), brain-derived neurotrophic factor (BDNF) and of the tropomyosin receptor kinase B receptor (Trk-B). Results showed an innately up-regulation of the CRFergic system, mediating negative mood and stress responses, as well as an inherent up-regulation of the anti-stress N/OFQ system, both in the amygdala (AMY) and bed nucleus of the stria terminalis (BNST) of msP rats. The up-regulation of this latter system may reflect an attempt to buffer the negative condition elicited by the hyperactivity of pro-stress mechanisms since results showed that voluntary alcohol consumption dampened N/OFQ. Alcohol exposure also reduced the expression of dynorphin and CRF transmissions in the AMY of msP rats. In the BNST, alcohol intake led to a more complex reorganization of these systems increasing receptor transcripts in msP rats, along with an increase of CRF and a decrease of N/OFQ transcripts, respectively. Moreover, mimicking the effects of alcohol in the AMY we observed that the activation of NOP receptor by intracerebroventricular administration of N/OFQ in msP rats caused an increase of BDNF and a decrease of CRF transcripts. Our study indicates that both stress and anti-stress mechanisms are dysregulated in the extended AMY of msP rats. The voluntary alcohol drinking, as well as NOP agonism, have a significant impact on neuropeptidergic systems arrangement, bringing the systems back to normalization.

Informacja